SCHEMBL504983

SCHEMBL504983

N#CNC(=Nc1ccncc1)NCCCCCCCCCCOc1ccc(Cl)cc1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 4/20 0.61
CYP3A4 P08684 1/20 0.61
CYP2D6 P10635 1/20 0.61
CYP2C9 P11712 1/20 0.61
CYP2C19 P33261 1/20 0.61
IKBKB O14920 1/20 0.59
ALDH3A1 P30838 1/20 0.39
KMT2A Q03164 1/20 0.38
HRH4 Q9H3N8 2/20 0.38
ALDH1A1 P00352 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
LARS1 Q9P2J5 1/20 0.37
HRH3 Q9Y5N1 2/20 0.36
HRH2 P25021 1/20 0.36
HRH1 P35367 1/20 0.36
KCNH2 Q12809 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL504864 1.00 NAMPT (0.61) NAMPTCYP3A4CYP2D6CYP2C9CYP2C19
Chs-828 SCHEMBL504892 1.00 NAMPT (0.61) NAMPTCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL504126 1.00 NAMPT (0.61) NAMPTCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL505053 1.00 NAMPT (0.61) NAMPTCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL504863 1.00 NAMPT (0.61) NAMPTCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL504982 1.00 NAMPT (0.61) NAMPTCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL504997 1.00 NAMPT (0.61) NAMPTCYP3A4CYP2D6CYP2C9CYP2C19
Chs-828 SCHEMBL504151 1.00 NAMPT (0.61) NAMPTCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL505054 1.00 NAMPT (0.61) NAMPTCYP3A4CYP2D6CYP2C9CYP2C19
Chs-828 SCHEMBL504150 1.00 NAMPT (0.61) NAMPTCYP3A4CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120029036-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING PYRIDYL CYANOGUANIDINE, PROCESS FOR PREPARING THE SAME AND USE THEREOF TIANJIN MICHELE SCI-TECH DEVELOPMENT CO., LTD. (CN) 2012-02-02 US claimed
EP-2394649-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDYL CYANOGUANIDINES, PREPARATION METHODS AND USES THEREOF Tianjin Hemay Bio-Tech Co., Ltd. (CN) 2011-12-14 EP claimed
US-20120029036-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING PYRIDYL CYANOGUANIDINE, PROCESS FOR PREPARING THE SAME AND USE THEREOF TIANJIN MICHELE SCI-TECH DEVELOPMENT CO., LTD. (CN) 2012-02-02 US disclosed
EP-2394649-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDYL CYANOGUANIDINES, PREPARATION METHODS AND USES THEREOF Tianjin Hemay Bio-Tech Co., Ltd. (CN) 2011-12-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120029036-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING PYRIDYL CYANOGUANIDINE, PROCESS FOR PREPARING THE SAME AND USE THEREOF PLPBP, PYGL, QDPR NAMPT 511/4885CYP3A4 117/4885CYP2D6 101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.